Eliem Therapeutics News

ELYMDelisted Stock  USD 3.23  0.01  0.31%   
About 61% of Eliem Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Eliem Therapeutics suggests that many traders are alarmed. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over a week ago at news.google.com         
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Eliem Therapeutics Changes Name to Climb Bio
Yahoo News
over two months ago at news.google.com         
Eliem Therapeutics, Inc. Shares Sold by Driehaus Capital Management LLC - MarketBeat
Google News at Macroaxis
over two months ago at simplywall.st         
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly ...
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Private equity firms who have a significant stake must be disappointed along with institutions after...
Yahoo News
over two months ago at news.google.com         
Eliem Therapeutics to join the Russell 2000 and Russell 3000 indexes - MSN
Google News at Macroaxis
over two months ago at news.google.com         
500,000 Shares in Eliem Therapeutics, Inc. Acquired by Ally Bridge Group NY LLC - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Eliem Therapeutics Recent Strategic Pipeline Restructuring - Seeking Alpha
Google News at Macroaxis
over two months ago at investing.com         
Eliem therapeutics executive sells over 9,000 in company stock
Investing News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3
Macroaxis News
over two months ago at thelincolnianonline.com         
Eliem Therapeutics, Inc. Sees Significant Increase in Short Interest
news
over two months ago at thelincolnianonline.com         
Acquisition by Emily Pimblett of 5000 shares of Eliem Therapeutics subject to Rule 16b-3
news
over two months ago at finance.yahoo.com         
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Yahoo News
over three months ago at benzinga.com         
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems ...
benzinga news
over three months ago at news.google.com         
Eliem Therapeutics Executive Changes Amid Strategic Shift - TipRanks
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Eliem Therapeutics that are available to investors today. That information is available publicly through Eliem media outlets and privately through word of mouth or via Eliem internal channels. However, regardless of the origin, that massive amount of Eliem data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eliem Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eliem Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eliem Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eliem Therapeutics alpha.

Eliem Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
09/11/2024
2
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3
09/20/2024
3
500,000 Shares in Eliem Therapeutics, Inc. Acquired by Ally Bridge Group NY LLC - MarketBeat
09/24/2024
4
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN
11/20/2024

Other Consideration for investing in Eliem Stock

If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum